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Objective: We aimed to screen differentially expressed genes (DEGs) of ovarian surface epithelia in order to provide
beneficial help for early diagnosis and treatment of ovarian cancer with DNA microarrays.
Methods: We extracted the microarray expression profile GSE14407 from Gene Expression Omnibus database
which conducted gene expression profiling analysis of 12 ovarian surface epithelia (OSE) and 12 laser capture
microdissected serous ovarian cancer epithelia (CEPI) samples. The DEGs between OSE and CEPI were identified by
Limma package of R language. Cluster analysis was employed to compare the differences of gene expression
patterns between OSE and CEPI. Furthermore, DEGs were analyzed with Functional classification tool, GenMAPP
software and GENECODIS.
Results: We identified 1229 DEGs including 592 down-regulated genes and 637 up-regulated genes. Pathway
analysis showed that cell cycle was the most significant pathway and the DEGs related with cell cycle were almost
up-regulated. Module mining analysis showed that the up-regulated DEGs were related with signal transduction
while the down-regulated DEGs were related with lipid metabolism pathway and cytoskeletal structure.
Conclusion: The genes related with cell cycle, lipid metabolism and cytoskeletal structure may be the treatment
targets for ovarian cancer.
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Ovarian cancer is the fifth most common cause of cancer
deaths among women and is the leading cause of death
from gynecological neoplastic disease [1]. The average
5-year survival rate is approximately 40%; however, most
ovarian cancers are diagnosed when the disease has
progressed to the advanced stages III or IV. Patients with
advanced disease (stages III and IV) have a significantly
lower survival rate of only 10%–20% [2]. A high percent-
age of mortality results from low diagnosis rate. Survival
rates can approach 90% when ovarian cancer is diagnosed
at an early stage; however, early detection is challenging,
because the relatively nonspecific symptoms of ovarian
lesions may be overlooked until abdominal distension by
ascites fluid or by large tumor masses becomes unmis-
takable. Even with extensive surgical debulking and* Correspondence: yinghuanchun@gmail.com
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reproduction in any medium, provided the oraggressive chemotherapy, the prognosis for women with
ovarian cancer currently is not hopeful.
The conventional view is that approximately 90% of
ovarian cancers are derived from the single-cell layer of
surface epithelium that surrounds the ovary [3]. As the
ovarian epithelium transforms into a malignant pheno-
type, it differentiates into several subtypes that have been
categorized into serous, mucinous, endometrioid and
clear cell carcinoma, based on their morphology rather
than their genotype [4]. Epithelial ovarian cancers show a
high degree of genetic heterogeneity as a result of mu-
tations, silencing, and deletions. Since changes in gene
expression, either through mutation, epigenetic regulation,
or differential splicing events, influence tumor develop-
ment, progression, drug responsiveness and ultimately the
survival of the patient, the identification of the tumor
subtype and its genetic fingerprint is essential. Several
studies have indicated that different histological subtypes
of ovarian carcinoma are associated with different causes
and underlying mechanisms, including gene amplification,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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theless, the origin and causes of ovarian carcinoma remain
to be elucidated.
The development of microarray technology has pro-
vided new insights into cancer diagnosis and treatment.
Large-scale microarray studies in breast cancer have
succeeded in clarifying 5 molecular subtypes based on
gene expression profiles and in developing genomic bio-
markers for predicting recurrence in early breast cancer
[6]. Thus, breast cancer treatment strategies are being
stratified according to molecular characteristics. In con-
trast, there are no gene expression signatures with high
accuracy and reproducibility for clinical diagnosis and
management in patients with ovarian cancer because
there is a paucity of ovarian cancer samples available
for microarray analysis compared with breast cancer.
Although TP53 somatic mutation is present in almost all
high-grade serous ovarian cancer and plays an important
role in the pathogenesis [7,8], high-grade serous ovarian
cancer exhibits much biological and molecular hetero-
geneity that should be considered when developing a
novel therapeutic strategy for ovarian cancer [8,9]. A
better understanding of the molecular mechanisms lead-
ing to ovarian cancer may provide new opportunities for
the development of strategies for diagnosis and therapy.
In the present study, we compared the gene expression
profile between ovarian surface epithelia (OSE) and laser
capture microdissected serous ovarian cancer epithelia
(CEPI) samples. Differentially expressed genes (DEGs)
were analyzed using gene ontology (GO), molecular
pathway, and gene set enrichment analysis algorithms
methods. Here we highlight progressive changes that
lead to a highly dysregulated cell cycle. These genes,
their gene products and the associated signaling path-




We extracted the microarray expression profile from the
study of Nathan J Bowen et al. [10], which was deposited
in GEO (Gene Expression Omnibus) database under ac-
cession number GSE14407. This study conducted gene
expression profiling analysis of 12 OSE and 12 CEPI sam-
ples on Affymetrix Human Genome U133 plus 2.0 Array.
Data preprocessing and DEGs analysis
The probe-level data in CEL files were converted into ex-
pression measures and the missing values were imputed
[11]. All the data were normalized before statistical ana-
lysis [12]. Limma package [13] of R language was used to
identify the DEGs between OSE and CEPI. P value was
adjusted through the Benjamini and Hochberg procedure[14]. A combination of false discovery rate (FDR) < 0.05
and the absolute value of logFc (Fold change) = 1 was used
as the threshold to determine the significance of gene ex-
pression difference.Comparing the difference of gene expression between
OSE and CEPI according to their expression patterns
Cluster analysis for genome-wide expression data from
DNA microarray hybridization uses standard statistical
algorithms to arrange genes according to similarity in
pattern of gene expression. The output is displayed
graphically, conveying the clustering and the underlying
expression data simultaneously in a form intuitive for
biologists. We used cluster analysis for comparing the
difference of gene expression patterns between OSE and
CEPI samples.Gene set enrichment analysis for DEGs
Individual gene analysis (IGA) evaluates the significance
of individual genes (approved by Ethical Committee of
Shengjing Hospital of China Medical University) between
two groups of samples compared. The main problems of
IGA originate from the use of the cutoff threshold value.
First, the final result of IGA is significantly affected by the
selected threshold, which is normally chosen arbitrarily.
Second, many genes with moderate but meaningful ex-
pression changes are discarded by the strict cutoff value,
which leads to a reduction in statistical power. Gene set
analysis (GSA) methods free from the problems of the
‘cutoff-based’ methods. GSA directly scores pre-defined
gene sets for differential expression and especially aims to
identify gene sets with ‘subtle but coordinated’ expression
changes that cannot be detected by IGA methods. The
key principle is that even weak expression changes in indi-
vidual genes gathered to a large gene set can show a sig-
nificant pattern.
Functional Classification Tool used agglomerative clus-
tering algorithm technique for mining the complex func-
tion of gene set [15]. We analyzed the up-regulated genes
and down-regulated genes separately with cluster method.
FDR < 0.05 was set as threshold.Pathway analysis for DEGs
GenMAPP [16] (Gene Map Annotator and Pathway
Profiler) is a free, open-source, stand-alone application
for visualizing, analyzing and sharing genome-scale data
in the context of biological pathways. GenMAPP allows
users to view and analyze genome-scale data, such as
microarray data, on biological pathways, GO terms or
any other grouping of genes. In the present study,
GenMAPP was used to identify which pathways are af-
fected by analyzing DEGs in ovarian cancers.
Figure 1 The box plots generated using the normalized data of 12 ovarian surface epithelia (OSE) and 12 ovarian cancer epithelia
(CEPI) samples. OSE and CEPI samples are indicated with light green and deep green boxes respectively. Black line in each box represents the
median of each sample. All the black lines are almost in the same position indicating minimum variability in these datasets.
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Gene sets reflect biological modules only approximately.
Only a subset of genes in a set may contribute to its
expression signature, and different gene sets may have
similar signatures across the arrays, owing to either an
overlap between the gene sets or co-regulation of non-
overlapping gene sets. When several gene sets (a cluster)
have similar signatures, we extracted from this cluster a
core module, which both refines the gene composition
of each gene set and combines several related gene sets.
This module more closely reflects the genes that participateFigure 2 Hierarchical clustering and gene ontology (GO) enrichment
cancer epithelia (CEPI) samples. The heat map (left) was generated by Z
Plus 2.0 3 to display the relative expression levels of genes (rows) differenti
downregulated) in 12 OSE and 12 CEPI samples (columns). Uniquely, enrich
significances corrected by false discovery rate (FDR), hypergeometric distribin a specific biological process, as it consists of the genes
whose expression profile corresponds to the signature of
the cluster [17].
We used GeneCodis software to integrate DEGs to
find groups of genes with similar biological meaning.
GeneCodis [18], a web-based application, is a tool for
singular and modular enrichment analysis that integrates
information of diverse nature (e.g. functional, regulatory
or structural) by looking for frequent patterns in the
space of annotations and computing their statistical rele-
vance. It can provide analysis of different annotations,of DEGs between ovarian surface epithelia (OSE) and ovarian
-score normalization of log2 expression values from Affymetrix HGU133
ally expressed (red = relatively upregulated; green = relatively
ed GO terms are listed for each set of DEGs and their statistical
ution p-values.
Figure 3 A GenMAPP schematic of cell cycle pathway genes. Genes significantly overexpressed in ovarian cancer epithelia samples (CEPI)
relative to ovarian surface epithelia (OSE) samples are colored red. The execution of the cell cycle is depicted from left to right. Genes involved in
maintaining G1 are generally donregulated (Green) while genes involved in G1 to S progression, G2, and M are upregulated (Red) in CEPI.
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cellular component, and molecular function), KEGG path-
ways, InterPro Motifs, and Swiss-Prot keywords. This
integrative capacity sheds light on different aspects of the
same information and provides a more accurate interpre-
tation of the data.
Results
DEGs analysis
We obtained publicly available microarray dataset GSE14407
from GEO database. After preprocessing and normali-
zation, at the threshold of FDR < 0.05 and |logFC| > 1, we
got 1229 DEGs which included 592 down-regulated genes
and 1637 up-regulated genes.
Differential gene expression patterns between OSE cells
and CEPI
The hierarchical clustering algorithm was used to compare
the differential gene expression patterns between OSE and
CEPI samples. The clustered images in Figure 1 is the
presence of large contiguous patches of color representing
groups of genes that share similar expression patterns.From the colored Figure, we could see that there were
significant gene expression differences between OSE and
CEPI samples.Gene set enrichment analysis for DEGs
We mapped all the DEGs into Functional Classification
Tool and performed functional enrichment analysis. The
results showed that most of the up-regulated DEGs in
CEPI were related with cell cycle (Figure 2, right side).Pathway analysis for DEGs
GenMAPP pathways, called MAPPs, contain a set of
gene or protein identifiers as well as graphical elements,
with the custom layouts depicting the relationships be-
tween genes and proteins. We mapped all the DEGs into
GenMAPP and obtained the most significant pathway-
cell cycle which included 9 up-regulated DEGs and 1
down-regulated DEGs (Figure 3). The only one down-
regulated DEG was in G1 phase. The DEGs in S, M, G2
phase were all up-regulated.
Figure 4 Module mining results. A and B are modules containing up-regulated DEGs; C and D are modules containing down-regulated DEGs.
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The down-regulated DEGs and up-regulated DEGs were
mapped into GENECODIS separately and four modules
were obtained individually (Figure 4). The up-regulated
DEGs in the 2 modules (Figure 4A and 4B) were related
with signal transduction), while the down-regulated
DEGs in the other 2 modules (Figure 4C and 4D) were
related with lipid metabolic process and cytoskeletal
structure (Table 1).
Discussion
In the present study, we have identified genes and
their functional categories that are altered in CEPI
samples. The gene expression profiles displays statisti-
cally significant changes in cell cycle, signal pathway,
metabolism and other functional categories that cor-
respond well with many of the morphological changes
and biological behaviors.
Dysregulation of the cell cycle is a hallmark of many
cancers and control and timing of the cell cycle involves
checkpoints and regulatory pathways that ensure the fi-
delity of DNA replication and chromosome segregation
[19]. These processes involve a large collection of key
molecules, which are excellent candidates for ovarian
cancer susceptibility variants. These include the cyclins
(CCNA1, CCNA2, CCNB1, CCNB2, CCND1, CCND2,
CCND3, CCNE1, CCNE2, CCNG1, CCNG2), cyclin-dependent kinases (CDKS: CDK1, CDK2, CDK4, CDK6,
CDK7, CDC2), CDK inhibitors (CDKN1A, CDKN1B,
CDKN2A, CDKN2B, CDKN2C, CDKN2D) and CDC2
regulators (CDC25A, CDC25B, CDC25C) [19]. In the
current study, CDK1, CDC6, CDC20, CDC25A,
CDC25B, CDC25C, CDC45, Bub1, ORC6 were up-
regulated. Studies have shown that up-regulation of
CDC6, CDC 20, CDC25 family and Bub1 has relation-
ship with human cancers.
Bub1 encodes a kinase involved in spindle checkpoint
function. Several studies have found high Bub1 levels in
subsets of breast and gastric cancers, and lymphomas.
Furthermore, independent studies of diverse tumor types
have identified Bub1 as a gene whose up-regulation cor-
relates with poor clinical prognosis [20].
It is reported that Cdc20 functions as an oncoprotein
to promote the development and progression of human
cancers [21]. Microarray studies have recently reported
overexpression of CDC20 in various tumors, such as
tumors of the oral cavity [22], stomach [23], brain (glio-
blastoma) [24], urinary bladder [25], uterine cervix [26],
and ovary [27]. Meta-analysis of cancer microarray data
also identifies CDC20 as one of the highly expressed
genes in various human cancer tissues [28]. Further-
more, expressions of specific genes including CDC20
consistently correlate with total functional aneuploidy
and are predictive of poor prognosis in several cancer
Table 1 Functional annotations for genes in modules A, B, C and D
Module GO-ID Corr p-value N Description
A
7187 1.33E-03 3 G-protein signaling, coupled to cyclic nucleotide
second messenger
19932 3.69E-03 3 Second-messenger-mediated signaling
9605 2.83E-03 4 Response to external stimulus
7186 1.64E-04 5 G-protein coupled receptor protein signaling pathway
7166 3.34E-03 5 Cell surface receptor linked signaling pathway
42221 4.01E-03 5 Response to chemical stimulus
23033 9.18E-03 5 Signaling pathway
23052 8.46E-03 6 Signaling
50896 9.18E-03 6 Response to stimulus
19932 1.94E-03 5 Second-messenger-mediated signaling
B
7187 1.94E-03 4 G-protein signaling, coupled to cyclic nucleotide
second messenger
7186 1.94E-03 6 G-protein coupled receptor protein signaling pathway
19935 1.94E-03 4 Cyclic-nucleotide-mediated signaling
7166 3.96E-03 8 Cell surface receptor linked signaling pathway
1958 9.43E-03 2 Endochondral ossification
C
45104 0.0069735 2 Intermediate filament cytoskeleton organization
45103 0.0069735 2 Intermediate filament-based process
D
6665 3.9682E-07 4 Sphingolipid metabolic process
6643 3.9682E-07 4 Membrane lipid metabolic process
44255 3.6038E-06 5 Cellular lipid metabolic process
46519 0.000014759 3 Sphingoid metabolic process
6629 0.000017443 5 Lipid metabolic process
6644 0.00036681 3 Phospholipid metabolic process
19637 0.00038844 3 Organophosphate metabolic process
N: number of enriched genes; Corr p-value: p value was adjusted by Benjamini and Hochberg procedure.
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in serous epithelial ovarian cancer, overexpression of
CDC20 is a prognostic factor associated with clinical
stage of disease, irrespective of tumor grade [27].
The cell division cycle 25 (CDC25) families of proteins
is a group of highly conserved dual-specificity phospha-
tases. There are three isoforms: CDC25A, CDC25B and
CDC25C. They are key regulators of normal cell division
and the cell response to DNA damage, and play a funda-
mental role in transitions between cell cycle phases
during normal cell division, via the activation of CdK/
cyclin complexes. Their abnormal expression, detected
in a number of tumors, often correlated with a poor
clinical prognosis, implies that their dysregulation is in-
volved in malignant transformation [30]. In the context
of the progression of cell division, the A and B isoforms
of CDC25 have been reported as potential oncogenes,
being overexpressed in more than ten types of human
cancer, including prostate and breast cancers, as well as
vulvar squamous cell carcinomas. In contrast, CDC25Cis expressed at a far lower level in a limited number of
tumors [30].
Module analysis showed that the modules containing
the down-regulated DEGs were related with lipid meta-
bolic process and cytoskeletal structure. The modules
containing up-regulated DEGs were related with signal
transduction. In the last decade, the altered lipid meta-
bolism has increasingly been recognized as another com-
mon property of malignant cells [31,32]. Like glucose
metabolism, lipid metabolism in cancer cells is also reg-
ulated by the common oncogenic signaling pathways,
and is believed to be important for the initiation and
progression of tumors [32]. Some newly generated lipids
molecules, such as phosphatidic acid (PA), diacylglycerol
(DAG), and lysophosphatidic acid (LPA), also mediate
signal transduction in cancer cells [32]. These lipids
regulate a variety of cellular functions including cell
proliferation, survival and migration by either activating
other signaling proteins inside the cells, or binding to a
series of G protein-coupled receptors (GPCRs) on the
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lipid metabolic pathways, particularly drugs targeting the
mevalonate pathway, have been suggested to be valuable
in enhancing the effectiveness of epidermal growth factor
receptor-tyrosine kinase inhibitors (EGFR-TKIs) [33]. On
the other hand, oncogenic signaling pathways can regulate
lipid metabolism at multiple steps, including transcrip-
tional, translational and post-translational levels.
The cytoskeleton plays an important role in tumor cell
progression and events such as migration and invasion,
allowing the cells to adapt and survive in different mi-
croenvironments; compounds that regulate cytoskeleton
organization have been used as cancer therapeutics [34].
On the other hand, the organization of the cytoskeleton
affects cellular organization, adhesion complexes and
polarity, and vesicular transports. Creekmore et al. dem-
onstrate that cytoskeleton disorganization can have pro-
found effects on the subcellular localization of important
signaling intermediates, which ultimately may lead to
modulated signaling pathways contributing to ovarian
cancer development [4].
The complex molecular processes underlying the on-
set and development of epithelial ovarian cancer is only
beginning to be unraveled. Our results indicate that cell
cycles, lipid metabolic pathways, cytoskeleton changes and
some signal transduction pathways are involved in the
establishment and development of ovarian cancer. While
many of these pathways have previously been either dir-
ectly or indirectly implicated in ovarian cancer, detailed
network analyses of our gene expression data led to the
identification of linkages between these pathways attribu-
table to the altered expression of key regulatory genes.
Synopsis
Our results indicate cell cycles, lipid metabolic pathways,
cytoskeleton changes and some signal transduction path-
ways are involved in the establishment and development
of ovarian cancer.
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